The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma
Open accessAbstract
BACKGROUND IrAEs typically occur within 4 months of starting anti-PD1-based therapy (anti-PD1 +/- anti-CTLA4), but delayed irAEs (onset >12 months after commencement) can also occur. This study describes the incidence, nature and management of delayed irAE in patients receiving anti-PD1-based immunotherapy. METHODS Patients with delayed irAEs from 20 centres were studied. The incidence of delayed irAEs was estimated as a proportion of melanoma patients treated with anti-PD1-based therapy and surviving >1 year. Onset, clinical features, management and outcomes of irAEs were examined. RESULTS 118 patients developed a total of 140 delayed irAEs (20 after initial combination with anti-CTLA4); with an estimated incidence of 5.3% (95% CI 4.0-6.9, 53/999 patients at sites with available data). The median onset of delayed irAE was 16 months (range 12-53). 87 patients (74%) were on anti-PD1 at irAE onset, 15 patients (12%) were <3 months from last dose, 16 patients (14%) were >3 months from last dose of anti-PD1. The most common delayed irAEs were colitis, rash and pneumonitis; 55 of all irAEs (39%) were ≥G3. Steroids were required in 80 patients (68%), as well as an additional immunosuppressive agent in 27 patients (23%). There were two irAE-related deaths: encephalitis with onset during anti-PD1, and a multiple organ-irAE with onset 11 months after ceasing anti-PD1. Early irAEs (<12 months) had also occurred in 69 patients (58%), affecting a different organ from the delayed irAE in 59 patients (86%). CONCLUSIONS Delayed irAEs occur in a small but relevant subset of patients. Delayed irAEs are often different from previous irAE, may be high grade and can lead to death. They mostly occur in patients still receiving anti-PD1. The risk of delayed irAE should be considered when deciding duration of treatment in responding patients. However, patients who stop treatment may also rarely develop delayed irAE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Self-citationFive-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
Self-citationHaanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Adhikari, C., Bierman, C., van de Wiel, B. A., Scolyer, R. A., Krijgsman, O., Sikorska, K., Eriksson, H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30151-2 · Cited by 537
Self-citationImmune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
Braaten, T. J., Brahmer, J. R., Forde, P. M., Le, D., Lipson, E. J., Naidoo, J., Schollenberger, M., Zheng, L., Bingham, C. O., Shah, A. A., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216109 · Cited by 230
Johnson, D. B., McDonnell, W. J., Gonzalez-Ericsson, P. I., Al-Rohil, R. N., Mobley, B. C., Salem, J.-E., Wang, D. Y., Sanchez, V., Wang, Y., Chastain, C. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0523-2 · Cited by 176
Self-citationJohnson, D. B., Reynolds, K. L., Sullivan, R. J., Balko, J. M., Patrinely, J. R., Cappelli, L. C., Naidoo, J., & Moslehi, J. J. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30107-8 · Cited by 118
Self-citation
Cited by
Immune checkpoint inhibitors in melanoma
Carlino, M. S., Larkin, J., & Long, G. V. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01206-x · Cited by 1,185
Self-citationImmune-checkpoint inhibitors: long-term implications of toxicity
Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00600-w · Cited by 982
Self-citationOverall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Dent, R., McArthur, H., Pusztai, L., Kümmel, S., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2409932 · Cited by 561
Metadata
- Authors
- Owen, C. N., Bai, X., Quah, T., Lo, S. N., Allayous, C., Callaghan, S., Martínez-Vila, C., Wallace, R., Bhave, P., Reijers, I. L. M., Thompson, N., Vanella, V., Gerard, C. L., Aspeslagh, S., Labianca, A., Khattak, A., Mandala, M., Xu, W., Neyns, B., Michielin, O., Blank, C. U., Welsh, S. J., Haydon, A., Sandhu, S., Mangana, J., McQuade, J. L., Ascierto, P. A., Zimmer, L., Johnson, D. B., Arance, A., Lorigan, P., Lebbé, C., Carlino, M. S., Sullivan, R. J., Long, G. V., & Menzies, A. M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 32
- Issue
- 7
- Pages
- 917-925
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3148902978
- Cited by
- 172
- References
- 8
- FWCI
- 10.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. https://app.cochat.ai/papers/10.1016/j.annonc.2021.03.204
- The paper
- Owen, C. N., Bai, X., Quah, T., Lo, S. N., Allayous, C., Callaghan, S., Martínez-Vila, C., Wallace, R., Bhave, P., Reijers, I. L. M., Thompson, N., Vanella, V., Gerard, C. L., Aspeslagh, S., Labianca, A., Khattak, A., Mandala, M., Xu, W., Neyns, B., . . . Menzies, A. M. (2021). Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Annals of Oncology. https://doi.org/10.1016/j.annonc.2021.03.204
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.